Insider · CIK 0001883290
Jason Cavalier
Files at LYRA (Lyra Therapeutics, Inc.). First filing Jul 14, 2025, latest Jan 8, 2026.
In brief
Jason Cavalier files SEC Form 4 as CFO at LYRA (Lyra Therapeutics, Inc.). Since Jul 14, 2025, Jason Cavalier has reported 0 open-market buys worth $0 and 2 open-market sells worth $8,681, the latest filed on Jan 8, 2026.
A track record needs three past buys with six months of prices behind them; Jason Cavalier has 0, so none is measured yet.
The newest scored trade: sold $2,587 of LYRA on Jan 6, 2026, filed Jan 8, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $2,587.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LYRA: Lyra Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Lyra Therapeutics, Inc. | $2,587 769 shares | -0% | +17% from low-88% from high | |
| 10Weak | Lyra Therapeutics, Inc. | $6,094 684 shares | -0% | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | LYRA Lyra Therapeutics, Inc. | DDisposition to issuer Common Stock | -667 | $0.00 | $0 | 517,880 | Apr 3, 2026 |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -769 | $3.36 | $2,587 | 518,547 | Jan 8, 2026 |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -684 | $8.91 | $6,094 | 519,316 | Jul 14, 2025 |
| Jan 8, 2025 | LYRA Lyra Therapeutics, Inc. | AGrant or award Common Stock | +420,000 | $0.00 | $0 | 520,000 | Jan 10, 2025 |
| Oct 16, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 100,000 | Oct 18, 2024 |
Questions about Jason Cavalier
Answered from the filings on this page, as of the latest one.
Is Jason Cavalier buying or selling?
In the last 12 months Jason Cavalier reported 0 open-market buys worth $0 and 1 open-market sell worth $2,587 on SEC Form 4; the latest was sold $2,587 of LYRA on Jan 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Jason Cavalier's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jason Cavalier has 0.
Where does Jason Cavalier file Form 4?
Jason Cavalier has filed Form 4 at LYRA (Lyra Therapeutics, Inc.) as Principal Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.